Castle Biosciences Files 8-K on Financial Condition & Operations

Ticker: CSTL · Form: 8-K · Filed: 2024-01-08T00:00:00.000Z

Sentiment: neutral

Topics: financial-condition, regulation-fd, corporate-update

TL;DR

**Castle Biosciences just filed an 8-K, signaling upcoming financial or operational news.**

AI Summary

Castle Biosciences, Inc. filed an 8-K on January 8, 2024, reporting an event that occurred on January 7, 2024. This filing indicates that the company is providing an update on its 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure'. This matters to investors because it signals that Castle Biosciences is likely to release new financial information or operational updates, which could impact the stock price (CSTL) depending on the nature of the disclosure.

Why It Matters

This filing indicates that Castle Biosciences is preparing to disclose important financial or operational updates, which could directly influence investor perception and the company's stock valuation.

Risk Assessment

Risk Level: low — This 8-K is a procedural filing indicating an upcoming disclosure, not a disclosure of negative information itself, so the immediate risk is low.

Analyst Insight

A smart investor would monitor Castle Biosciences' (CSTL) news channels closely for the actual financial or operational disclosure that this 8-K foreshadows, as it will contain the substantive information impacting the stock.

Key Players & Entities

Forward-Looking Statements

FAQ

What is the primary purpose of this 8-K filing by Castle Biosciences, Inc.?

The primary purpose of this 8-K filing is to report an event related to 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure' that occurred on January 7, 2024.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on January 7, 2024.

What is the trading symbol for Castle Biosciences, Inc.?

The trading symbol for Castle Biosciences, Inc. is CSTL, and its common stock is registered on The Nasdaq Global Market.

What is the business address of Castle Biosciences, Inc.?

The business address of Castle Biosciences, Inc. is 505 S. Friendswood Drive, Suite 401, Friendswood, Texas 77546.

Under which items of Form 8-K is this filing made?

This filing includes information under 'ITEM INFORMATION: Results of Operations and Financial Condition', 'ITEM INFORMATION: Regulation FD Disclosure', and 'ITEM INFORMATION: Financial Statements and Exhibits'.

Filing Stats: 659 words · 3 min read · ~2 pages · Grade level 10 · Accepted 2024-01-08 07:04:28

Key Financial Figures

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 7, 2024, Castle Biosciences, Inc. (the "Company") issued a press release announcing certain preliminary performance results for the fourth quarter of 2023 and for the year ended December 31, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information contained or incorporated in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended (the "Securities Act"), except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 8, 2024, the Company made available the slide presentation attached hereto as Exhibit 99.2. Information from this slide presentation may also be used by the management of the Company in future meetings regarding the Company. The information contained or incorporated in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.2, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press release issued January 7, 2024. 99.2 Slide presentation. 104 Inline XBRL for the cover page of this Current Report on Form 8-K.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CASTLE BIOSCIENCES, INC. By: /s/ Frank Stokes Frank Stokes Chief Financial Officer Date: January 8, 2024

View on Read The Filing